Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 43,229 shares, a drop of 91.3% from the December 15th total of 494,378 shares. Approximately 7.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,635,913 shares, the short-interest ratio is presently 0.0 days. Based on an average daily trading volume, of 1,635,913 shares, the short-interest ratio is presently 0.0 days. Approximately 7.0% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BDRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen raised Biodexa Pharmaceuticals to a “sell” rating in a report on Saturday, December 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

Shares of NASDAQ:BDRX opened at $2.29 on Wednesday. The company’s fifty day moving average is $4.20 and its two-hundred day moving average is $6.16. Biodexa Pharmaceuticals has a 12-month low of $2.22 and a 12-month high of $92.00.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.